Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind multicenter trial of Songling Xuemai Kang Capsules for premature ventricular contractions caused by non-organic heart disease
CTR20253222Phase 2Active
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- Aug 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Songling Xuemai Kang Capsules in Premature ventricular complexes (PVC), sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd.. Started Aug 2025; status: active.
02
Drugs
Songling Xuemai Kang Capsules
03
Conditions
Premature ventricular complexes (PVC)
Beyond the preview
Go deeper on CTR20253222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253222.